Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arvinas Inc ARVN

Healthcare
Arvinas, Inc. is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The Company uses its PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein... see more

Recent & Breaking News (NDAQ:ARVN)

Arvinas Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021

GlobeNewswire April 5, 2021

Arvinas to Participate in Upcoming Virtual Investor Conferences

GlobeNewswire March 10, 2021

Arvinas Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

GlobeNewswire March 1, 2021

Arvinas to Present at the Guggenheim Healthcare Talks: 2021 Oncology Day

GlobeNewswire February 8, 2021

Arvinas, Inc. Announces Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire December 28, 2020

Arvinas, Inc. Announces Pricing of $400 Million Public Offering of Common Stock

GlobeNewswire December 15, 2020

Arvinas, Inc. Announces Proposed Offering of Common Stock

GlobeNewswire December 14, 2020

Arvinas Releases Interim Clinical Data Further Demonstrating the Powerful Potential of PROTAC® Protein Degraders ARV-471 and ARV-110

GlobeNewswire December 14, 2020

Arvinas to Host Webcast Presentation of New Clinical Data from ARV-471 and ARV-110 PROTAC® Protein Degrader Development Programs

GlobeNewswire December 11, 2020

Arvinas to Participate in Upcoming Virtual Investor Conferences

GlobeNewswire November 25, 2020

Arvinas Reports Third Quarter 2020 Financial Results and Provides Corporate Update

GlobeNewswire November 5, 2020

Arvinas Announces Pipeline Programs Targeting Validated and Classically "Undruggable" Disease-Causing Proteins

GlobeNewswire October 14, 2020

Arvinas to Present at the 3rd Annual Targeted Protein Degradation Summit

GlobeNewswire October 6, 2020

Arvinas to Present at the Citi 15th Annual BioPharma Virtual Conference

GlobeNewswire September 4, 2020

Arvinas to Present at the 2020 Wedbush PacGrow Virtual Healthcare Conference

GlobeNewswire August 7, 2020

Arvinas Reports Second Quarter 2020 Financial Results and Provides Corporate Update

GlobeNewswire August 4, 2020

Arvinas Appoints Wendy Dixon, Ph.D., to its Board of Directors

GlobeNewswire June 29, 2020

Arvinas to Present Virtually at the BMO 2020 Prescriptions for Success Healthcare Conference

GlobeNewswire June 17, 2020

Arvinas Appoints Linda Bain to its Board of Directors

GlobeNewswire June 11, 2020

Arvinas to Present Virtually at the Goldman Sachs 41st Annual Global Healthcare Conference

GlobeNewswire June 5, 2020